Asparaginase

Asparaginase

Asparaginase is a drug that is used in the treatment of acute lymphatic leukemia (ALL), lymphoblastic lymphoma (LBL), and certain types of blood cancers. It works by breaking down the amino acid asparagine and may block the growth of the tumour cells that requires asparagine to grow. It is an enzyme obtained chemically from the bacterium Escherichia coli (E.coli), Erwinia chrysanthemi, Pegylated, fungi, algae, and many more. Research and development studies are being carried out for the expansion of its application area in various fields such as nanomedicine, biomedical engineering, and many more.

The Asparaginase Market is expected to grow at a steady rate of around 16.4% owing to the expansion of pharmaceutical industry R&D and an increase in FDA approvals for asparaginase drugs. According to the data from the Food Drug Administration (FDA) report, on June 30, 2021, the FDA approved Erwinia chrysanthemi (recombinant)-rywn (Rylaze) a new form of asparaginase. Rylaze was approved as a part of the treatment regime in children and adults for the treatment of aggressive blood cancer that resembles ALL. Additionally, in November 2022, Jazz Pharmaceutical plc announced the USFDA approval for supplementary biologics license application (SBLA) to the intramuscular (IM) dosing for Rylaze FDA seeking (Asparaginase Erwinia chrysanthemi (recombinant)-rywn, for use as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL in adult and pediatric patients. Thus, with expansion in the pharmaceutical industry, R&D, and increased FDA approvals, there will be a positive impact on market growth during the forecast period.

• Based on Type, the market is segmented into Escherichia coli (E.coli), Erwinia chrysanthemi, and Pegylated. E.coli category held the dominant share in the market in 2021. This is mainly due to the increase in demand for E.Coli asparaginase in cancer treatment According to the study on Comparative pharmacokinetic studies of three asparaginase preparations conducted by the University of Rochester, New York. Erwinia chrysanthemi asparaginase has a much shorter biological half-life (0.65 days) than E.coli (1.44 days) or PEG asparaginase. Hence E.coli is widely used in the treatment of ALL and is the preferred drug of choice for the treatment of cancer. Thus the increased demand for E.coli for cancer treatment is anticipated to drive the market for asparaginase positively during the forecast period.
• Based on Application, the market is segmented into acute lymphoblastic leukemia, acute myeloid leukemia, and Other (Hodgkin’s disease). The acute lymphoblastic leukemia segment is expected to grow with a high CAGR during the forecast period. this is attributed to its increase use in the treatment of lymphoproliferative disorders and lymphoma. According to the Institute of Health Metrics and Evaluation, in 2019 about 153,000 new cases of acute lymphoblastic leukemia were reported globally. These are the elements that are anticipated to fuel the market during the forecast period.
• Based on End-use, the market is segmented into hospitals, clinics, retail pharmacy and online pharmacy. Hospitals held the dominant share of the market in 2021. The rapidly growing health infrastructure is expected to increase the demand for asparaginase during the forecasting period, leading to increase research activities, along with this rising investment in research and development by the key market players. For instance, in 2019 University of Millions Chicago, secured funding of about USD 1 million for aspargine for the development of less toxic chemotherapy use in the treatment of ALL.
• For a better understanding of the market adoption of asparaginase, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia Pacific is anticipated to grow with a significant CAGR during the forecast period, owing to factors, including the rising prevalence of ALL and LBL across the region. Furthermore, the increase in research and development activity in the region is anticipated to boost market growth positively. For instance, in India, in March 2021, the Indian Institute of Technology (IIT) Indore developed a new protein, an engineering approach, to treat lymphoblastic lymphoma with an acute side effect.
• Some of the major players operating in the market include Jazz Pharmaceuticals plc, Servier Pharmaceutical LLC, medac GmbH, Kyowa Kirin co, ltd., Taj Pharmaceuticals Limited., Creative Enzymes.,Bio Vendor R&D, Gennova Biopharmaceuticals Limited., Actiza Pharmaceutical Private Limited, Porton Biopharma